Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TERF2 interacting protein pseudogene 1 (TERF2IPP1) is classified as a pseudogene, which means it is a genomic DNA sequence similar to a known gene but generally non-functional because it is not transcribed into a functional protein product. Pseudogenes often arise from gene duplication or retrotransposition events but lack regulatory elements or contain disabling mutations. TERF2IPP1, as its name suggests, is related by sequence similarity to the TERF2 interacting protein (TERF2IP; also known as RAP1), but current evidence does not support the existence of a protein product encoded by TERF2IPP1, nor any characterized biological role. No information suggests this pseudogene has significance as a drug target, biomarker, or involvement in disease, and it should not be confused with the functionally relevant gene TERF2IP, which is an essential component of the shelterin complex involved in telomere protection. This entry appears to be for a human pseudogene, not an active target protein or receptor. The functional gene/protein of interest in telomere biology is TERF2IP (Telomeric repeat-binding factor 2-interacting protein 1, RAP1), which is not the same as TERF2IPP1. There is no evidence that TERF2IPP1 is implicated in human disease or has any known molecular or clinical relevance. If a drug target or receptor was intended, the canonical active name would be TERF2 interacting protein (TERF2IP), not TERF2IPP1. Summary: TERF2 interacting protein pseudogene 1 (TERF2IPP1) is a genomic pseudogene with no known functional product, drug interactions, or disease associations. If a biologically relevant telomere-associated target is required, refer instead to TERF2IP (repressor activator protein 1, RAP1).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TERF2 interacting protein pseudogene 1 (TERF2IPP1).